BIETTI CRYSTALLINE CORNEORETINAL DYSTROPHY
Clinical trials for BIETTI CRYSTALLINE CORNEORETINAL DYSTROPHY explained in plain language.
Never miss a new study
Get alerted when new BIETTI CRYSTALLINE CORNEORETINAL DYSTROPHY trials appear
Sign up with your email to follow new studies for BIETTI CRYSTALLINE CORNEORETINAL DYSTROPHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental gene therapy offers hope for rare blindness condition
Disease control ENROLLING_BY_INVITATIONThis study provides ZVS101e, a gene therapy, to 32 people with Bietti crystalline corneoretinal dystrophy (BCD) who were in the control group of a previous Phase III trial. The therapy uses a harmless virus to deliver a working gene to the eye, aiming to slow vision loss. The mai…
Matched conditions: BIETTI CRYSTALLINE CORNEORETINAL DYSTROPHY
Phase: NA • Sponsor: Chigenovo Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Gene therapy injection aims to restore sight in rare eye disease
Disease control OngoingThis study tests a single injection of ZVS101e gene therapy for people with Bietti's crystalline dystrophy, a rare inherited condition that leads to progressive vision loss. The therapy delivers a working copy of the CYP4V2 gene directly to the retina. Researchers will measure wh…
Matched conditions: BIETTI CRYSTALLINE CORNEORETINAL DYSTROPHY
Phase: PHASE3 • Sponsor: Chigenovo Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC